Francisco J. Esteva: What should be the primary endpoint for FDA registration trials in early-stage breast cancer?

Norman Ng: Cancer Treatment Revolution – Breakthroughs Soar, But Can We Afford the Future?

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Antibody-Drug Conjugates and Their Ocular Effects in Cancer Treatment: Efficacy and Toxicity

FDA Approved Brentuximab Vedotin Combo for Relapsed/Refractory LBCL

Maria (Masha) Babak: A significant step forward for advanced HR+ HER2-negative breast cancer

Tanja Obradovic: How current FDA policy can affect advances in AI

Dario Trapani: The potential implications on access of FDA vs EMA discrepancies

Vivek Subbiah: FDA approves new non-opioid pain drug – Journavx

Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer